Long-term safety of proton pump inhibitors: risks of gastric neoplasia and infections

Bibliography

• BLACK JW, DUNCAN WAM, DURANT CJ, GANELLIN CR, PARSONS EM: Definition and antagonism of histamine H2- receptors. Nature (1972) 236:385–390.
   PubMed Web of Science ®Google Scholar
• ••Article of considerable interesr.
   Google Scholar
• BODEMAR G, WALAN A: Maintenance treatment of recurrent peptic ulcer by cimetidine. Lancet (1978) 1(8061):403–407.
   PubMed Web of Science ®Google Scholar
• BURGET DW, CHIVERTON SG, HUNT RH: Is there an optimal degree of acid suppression for healing of duodenal ulcers? Gastroenterology (1990) 99:345–351.
   PubMed Web of Science ®Google Scholar
• RAUWS EAJ, TYTGAT GNJ: Cure of duodenal ulcer associated with eradication of Helicobacter pylori Lancet (1990) 335:1233–1235.
   Google Scholar
• •Article of interest.
   Google Scholar
• HOWDEN CW, CASTELL DO, COHENS, FRESTON JVV, ORLANDO RC, ROBINSON M: The rationale for continuous maintenance treatment of reflux esophagitis. Arch. hat. Med. (1995) 155:1465–1471.
   Google Scholar
• HATLEBAKK JG, HYGGEN A, MADSEN PH et al.: Heartburn treatment in primary care: randomised, double blind study for 8 weeks. Br. Med. (1999) 319:550–553.
   PubMed Web of Science ®Google Scholar
• PFEIFFER A, ROCHLITZ H, NOELKE Bet al.: Muscarinic receptors mediating acid secretion in isolated rat gastric parietal cells are of M3 type. Gastroenterology (1990) 98:218–222.
   Google Scholar
• SANDVIK AK, WALDUM HL, KLEVELAND PM, SCHULZE SOGNEN B: Gastrin produces an immediate and dose-dependent histamine release preceding acid secretion in the totally isolated, vascularly perfused rat stomach. Scand Gastroenterol. (1987) 22:803–808.
   PubMed Web of Science ®Google Scholar
• •Article of interest.
   Google Scholar
• WALDUM HL, SANDVIK AK, BRENNA E, PETERSEN H: Gastrin-histamine sequence in the regulation of gastric acid secretion. Gut (1991) 32:698–701.
   PubMed Web of Science ®Google Scholar
• WALAN A: Anticholinergics in the treatment of peptic ulcer. Scand.1. Gastroenterol. (1979) 14:84–95.
   Web of Science ®Google Scholar
• EULER AR, MURDOCK RH, WILSON TH, SILVEER MT, PARKER SE, POWERS L: Ranitidine is effective therapy for erosive esophagitis. Am. Gastroenterol. (1993) 88:520–524.
   PubMed Web of Science ®Google Scholar
• ROUFAIL W, BELSITO A, ROBINSON M, BARISH C, RUBIN A: Ranitidine for erosive esophagitis: a double-blind placebo-controlled study: Glaxo Erosive Esophagitis Study Group. Aliment. Pharmacol. Ther. (1992) 6:597–608.
   PubMed Web of Science ®Google Scholar
• FELLENIUS E, BERGLINDH T, SACHS G et al: Substituted benzimidazoles inhibit acid secretion by blocking (HK) ATPase. Nature (1981) 290:150–161.
   Google Scholar
• •Article of considerable interest.
   Google Scholar
• LIND T, CEDERBERG C, EKENVED G, HAGLUND U, OLBE L: Effect of omeprazole - a gastric proton pump inhibitor - on pentagastrin stimulated acid secretion in man. Gut (1983) 24:270–276.
   PubMed Web of Science ®Google Scholar
• WALLMARK B, SACHS G, MARDH S, FELLENIUS E: Inhibition of gastric (H++I(±) ATPase by the substituted benzimidazole, picoprazole. Biochim. Biophys. Acta (1983) 728:31–38.
   PubMed Web of Science ®Google Scholar
• SHARMA BK, WAKT RP, POUNDER RE,GOMES MD, WOOD EC, LOGAN LH: Optimal dose of oral omeprazole for maximal 24 hr decrease of intragastric acidity. Gut(1984) 25:957–964.
   PubMed Web of Science ®Google Scholar
• •Article of interest.
   Google Scholar
• SAGAR M, TYBRING G, DAHL M-L, BERTILSSON L, SEENSALU R: Effect of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism. Gastroenterology (2000) 119:670–676.
   PubMed Web of Science ®Google Scholar
• ANDERSSON T, ROHSS K, BREDBERG E, HASSAL-ALIN M: Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Aliment. Pharmacol. The]: (2001) 15:1563–1569.
   PubMed Web of Science ®Google Scholar
• SANDVIK AK, BRENNA E, WALDUM HL: Review article: the pharmacological inhibition of gastric acid secretion - tolerance and rebound. Aliment. Pharmacol Ther. (1997) 11:1013–1018.
   PubMed Web of Science ®Google Scholar
• FRESTON JW, MALAGELADA JR PETERSEN H, MCCLOY RF: Critical issues in the management of gastroesophageal reflux disease. Ear: Gastroenterol Hepatol (1995) 7:577–586.
   PubMed Web of Science ®Google Scholar
• JOELSON S, JOELSON I-B, LUNDBORG P, WALAN A, WALLANDER M-A: Safety experience from long-term treatment with omeprazole. Digestion (1992) 51:93–101.
   PubMed Web of Science ®Google Scholar
• LEWIS SJ, FRANCO S,YOUNG G, O'KEEFE JD: Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole. Aliment. Pharmacol The]: (1996) 10:557–561.
   PubMed Web of Science ®Google Scholar
• NWOKOLO CU, LOFT DE, HOLDER R, LANGMAN MJS: Increased incidence of bacterial diarrhoea in patients taking gastric acid antisecretory drugs. Ear: J. Gastroenterol Hepatol (1994) 6:697–699.
   Web of Science ®Google Scholar
• LEWIS SJ, FRANCO S, YOUNG G, O'KEEFE SJD: Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole. Aliment. Pharmacol The]: (1996) 10:557–561.
   PubMed Web of Science ®Google Scholar
• BRUNNER G, ATHMANN C, BOLDT JH: Reversible pheripheral edema in female patients taking proton pump inhibitors for peptic acid disease. Dig. Dis. Sci. (2001) 46:993–996.
   PubMed Web of Science ®Google Scholar
• WALDUM HL, LEHY T, BRENNA E et al.: Effect of the histamine-1 antagonist astemizole alone or with omeprazole on rat gastrin mucosa. Scand. Gastroenterol (1991) 26:23–35.
   PubMed Web of Science ®Google Scholar
• LICHTENBERGER LM: Importance of food in the regulation of gastrin release and formation. Am. J. Physiol (1982) 243:G429–G441.
   PubMed Web of Science ®Google Scholar
• WALSH JW, RICHARDSON CT, FORDTRAN JS: pH dependence of acid secretion and gastrin release in normal and ulcer subjects. J. Gin. Invest. (1975) 55:462–468.
   PubMed Web of Science ®Google Scholar
• •Article of interest.
   Google Scholar
• WILDER-SMITH CH, SPIRIG C, KRECH T, MERKI HS: Bactericidal factors in gastric juice. Eur.J Gastroenterol Hepatol (1992) 4:885–891.
   Web of Science ®Google Scholar
• BELL NJV, BURGET D, HOWDEN CW, WILKINSON J, HUNT RH: Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion (1992) 51:59–67.
   PubMed Web of Science ®Google Scholar
• KLINKENBERG-KNOL EC, FESTEN HPM, JANSEN J et al.: Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann. Int. Med. (1994) 121:161–167.
   PubMed Web of Science ®Google Scholar
• •Article of interest.
   Google Scholar
• WALDUM HL, SANDVIK AK, SYVERSEN U, BRENNA E: The enterochromaffin-like (ECL) cell. Physiological and pathophysiological role. Acta Oncol (1993) 32:141–147.
   Google Scholar
• BRENNA E, WALDUM HL: Studies of isolated parietal and enterochromaffin-like cells from the rat. Scand. Gastroenterol (1991) 26:1295–1306.
   PubMed Web of Science ®Google Scholar
• RYBERG B, TIELEMANS Y, AXELSONJ et al.: Gastrin stimulates the self-replication rate of enterochromaffin-like cells in the rat stomach. Gastroenterology (1990) 99:935–942.
   PubMed Web of Science ®Google Scholar
• BAKKE I, QVIGSTAD G, SANDVIK AK, WALDUM HL: The CCK-2 receptor is located on the ECL cell, but not on the parietal cell. Scand. Gastroenterol (2001) 36:1128–1133.
   PubMed Web of Science ®Google Scholar
• ••Article of considerable interest.
   Google Scholar
• JOHNSON LR, AURES D, HAKANSON R: Effect of gastrin on the in vivo incorporation of14C-leucine into protein of the digestive tract. Proc. Soc. Exp. Biol. Med. (1969) 132:996–998.
   PubMed Web of Science ®Google Scholar
• HAKANSON R, TIELEMANS Y, CHEN D, ANDERSSON K, MATTSSON H, SUNDLER F: Time-dependent changes in enterochromaffin-like cell kinetics in stomach of hypergastrinemic rats. Gastroenterology (1993) 105:15–21.
   PubMed Web of Science ®Google Scholar
• •Article of interest.
   Google Scholar
• WALDUM HL, BRENNA E, SANDVIK AK: Relationship of ECL cells and gastric neoplasia. Yale J. Biol. Med. (1998) 71:325–335.
   PubMed Web of Science ®Google Scholar
• •Article of interest.
   Google Scholar
• BRENNA E, WALDUM HL: Trophic effect of gastrin on the enterochromaffin like cells of the rat stomach: establishment of a dose response relationship. Gut (1992) 33:1303–1306.
   PubMed Web of Science ®Google Scholar
• BLAIR AJ, RICHARDSON CT, WALSH JN, FELDMAN M: Variable contribution of gastrin to gastric acid secretion after a meal in humans. Gastroenterology (1987) 92:944–999.
   PubMed Web of Science ®Google Scholar
• •Article of interest.
   Google Scholar
• SJOBLOM S-M, SIPPONEN P, KARONEN S-L, JARVINEN HJ: Argyrophil cell hyperplasia and carcinoid tumours in oxyntic mucosa of the stomach. Dependence on duration of pernicious anaemia. Ear: Gastroenterol Hepatol (1991) 31:153–157.
   Google Scholar
• •Article of interest.
   Google Scholar
• EISSELE R, BRUNNER G, SIMON B, SOLCIA E, ARNOLD R: Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology (1997) 112:707–717.
   PubMedGoogle Scholar
• FULLARTON GM, MCLAUCHLAN G, MACDONALD A, CREAN GP, MCCOLL KEL: Rebound nocturnal hypersecretion after four weeks treatment with an H2 receptor antagonist. Gut (1989) 30:449–454.
   PubMed Web of Science ®Google Scholar
• PREWETT EJ, HUDSON M, NWOKOLO CU, SAWYERR AM, POUNDER RE: Nocturnal intragastric acidity during and after a period of dosing with either ranitidine or omeprazole. Gastroenterology (1991) 100:873–877.
   PubMed Web of Science ®Google Scholar
• KLEVELAND PM, WALDUM HL, LARSSON H: Gastric acid secretion in the totally isolated, vascularly perfused rat stomach. A selective muscarinic-1 agent does, whereas gastrin does not, augment maximal histamine-stimulated acid secretion. Scand. Gastroenterol (1987) 22:705–713.
   Google Scholar
• •Article of interest.
   Google Scholar
• LARSSON H, CARLSSON E, RYBERG B, FRYKLUND J, WALLMARK B: Rat parietal cell function after prolonged inhibition of gastric acid secretion. Am. J. Physic] (1988) 254:G33–G39.
   Web of Science ®Google Scholar
• KAY AW: Effect of large doses of histamine on gastric secretion of HCI. Br. Med. (1953) 2:77–80.
   PubMed Web of Science ®Google Scholar
• WALDUM HL, ARNESTAD JS, BRENNA E, EIDE I, SYVERSEN U, SANDVIK AK: Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut (1996) 39:649–653.
   PubMed Web of Science ®Google Scholar
• ••Article of considerable interest.
   Google Scholar
• GILLEN D, WIRZ AA, ARDILL JE, MCCOLL KE: Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology (1999) 116:239–247.
   PubMed Web of Science ®Google Scholar
• PRAVEEN KR, VENZON DJ, FEIGENBAUM KM et al.: Gastric secretion in Zoninger-Ellison syndrome. Medicine (2001) 80:180–222.
   PubMedGoogle Scholar
• QVIGSTAD G, ARNESTAD JS, BRENNA E, WALDUM HL: Treatment with proton pump inhibitors induces tolerance to histamine-2 receptor antagonists in Helicobacter pylorknegative patients. Scand. Gastroenterol (1998) 33:1244–1248.
   PubMed Web of Science ®Google Scholar
• RASMUSSEN L, OSTER-JORGENSEN E, QVIST N, KRAGLUND K, HOVENDAL C, PEDERSEN SA: Short report: a double blind placebo-controlled trial of omeprazole on characteristics of gastric emptying in healthy subjects. Aliment. Pharmacol Then (1991) 5:85–89.
   PubMed Web of Science ®Google Scholar
• BENINI L, CASTELLANI G, BARDELLI E et al: Omeprazole causes delay in gastric emptying of digestible meals. Dig. Dis. ScL (1996) 41:469–474.
   PubMed Web of Science ®Google Scholar
• HAVU H: Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion (1986) 35(1):42–55.
   PubMedGoogle Scholar
• ••Article of considerable interest.
   Google Scholar
• POYNTER D: Long-term effects of reduced gastric acidity in laboratory animals. Digestion (1985) 31:174.
   Web of Science ®Google Scholar
• POYNTER D, PICK CR, HARCOURT RA et al.: Association of long lasting unsurmountable histamine H2 blockade and gastric carcinoid tumours in the rat. G u t (1985) 26:1284–1295.
   Google Scholar
• BORCH K, RENEVALL H, LIEDBERG G: Gastric endocrine cell hyperplasia and carcinoid tumors in pernicious anemia. Gastroenterology (1985) 88:638–648.
   PubMed Web of Science ®Google Scholar
• •Article of interest.
   Google Scholar
• SOLCIA E, CAPELLA C, FIOCCA R, RINDI G, ROSAI J: Gastric argyrophil carcinoidosis in patients with Zollinger-Ellison syndrome due to type 1 multiple endocrine neoplasia. A newly recognized association. Am. Surg. Pathol (1990) 14:503–513.
   PubMed Web of Science ®Google Scholar
• KOKKOLA A, SJOBLOM SM, HAAPIAINEN R, SIPPONEN P, PUOLAKKAINEN P, JÄRVINEN H: The risk of gastric carcinoma and carcinoid tumours in patients with pernicious anaemia. A prospective follow-up study. Scand. Gastroenterol (1998) 33:88–92.
   PubMed Web of Science ®Google Scholar
• •Article of interest.
   Google Scholar
• ZAMCHECK N, GRABLE E, LEY A, NORMAN L: Occurrence of gastric cancer among patients with pernicious anemia at the Boston City Hospital. N Engl. I Med. (1955) 252:1103–1110.
   PubMed Web of Science ®Google Scholar
• STOCKBROGGER RW, MENON GG, BEILBY JOW, MASON RR, COTTON PB: Gastroscopic screening in 80 patients with pernicious anaemia. Gut (1983) 24:1141–1147.
   PubMed Web of Science ®Google Scholar
• MCGUIGAN JE, TRUDEAU WL: Serum gastrin concentrations in pernicious anaemia. N. Eng/. I. Med. (1970) 282:358–361.
   PubMed Web of Science ®Google Scholar
• CREUTZFELDT W, LAMBERTS R, STOCKMANN F, BRUNNER G: Quantitative studies of gastric endocrine cells in patients receiving long-term treatment with omeprazole. Scand. Gastroenterol (1989) 24:122–128.
   Web of Science ®Google Scholar
• WALDUM HL, HAUGEN OA, ISAKSEN C, MECSEI R, SANDVIK AK: Are diffuse gastric carcinomas neuroendocrine tumours (ELC-omas)? Eur. I Gastroenterol Hepatol (1991) 3:245–249.
   Web of Science ®Google Scholar
• WALDUM HL, AASE S, KVETNOI I et al.: Neuroendocrine differentiation in human gastric carcinomas. Cancer (1998) 83:435–444.
   PubMed Web of Science ®Google Scholar
• ••Article of considerable interest.
   Google Scholar
• QVIGSTAD G, SANDVIK AK, BRENNAE, AASE S, WALDUM HL: Detection of chromogranin A in human gastric adenocarcinomas using a sensitive immunohistochemical technique. Histochem. J. (2000) 32:551–556.
   PubMedGoogle Scholar
• QVIGSTAD G, QVIGSTAD T, WESTRE B, SANDVIK AK, BRENNA E, WALDUM HL: Neuroendocrine differentiation in gastric adenocarcinomas associated with severe hypergastrinemia and/or pernicious anemia. APMIS (2002) 110:132–139.
   PubMed Web of Science ®Google Scholar
• •Article of interest.
   Google Scholar
• QVIGSTAD G, FALKMER S, WESTRE B, WALDUM HL: Clinical and histopathological tumour progression in ECL cell carcinoids ("ECLomas"). APMIS (1999) 107:1085–1093.
   PubMed Web of Science ®Google Scholar
• •Article of interest.
   Google Scholar
• POYNTER D, SELWAY SAM, PAPWORTH SA, RICHES SR: Changes in the gastric mucosa of the mouse associated with long lasting unsurmountable histamine H2 blockade. Gut (1986) 27:1338–1346.
   PubMed Web of Science ®Google Scholar
• WALDUM HL, RORVIK H, FALKMER S, KAWASE S: Neuroendocrine (ECL-cell) differentiation of spontaneous gastric carcinomas of cotton rats (Sigmodon hispidusl. Lab. Amin. Sci. (1999) 49:241–247.
   PubMedGoogle Scholar
• SAFHOLM C, HAVU N, FORSSELL H, SUNDELL G, MATTSSON H: Effect of 7 years' daily oral administration of omeprazole to beagle dogs. Digestion (1994) 55:139–147.
   PubMed Web of Science ®Google Scholar
• HAVU N, MATTSSON H, EKMAN L, CARLSSON E: Enterochromaffin-like cell carcinoids in the rat gastric mucosa following long-term administration of ranitidine. Digestion (1990) 45:189–195.
   PubMed Web of Science ®Google Scholar
• EASON CT, SPENCER AJ, PATTISONA, HOWELLS DD, HENRY DC, BONNER FW: Species variations in gastric toxicity following chronic administration of ciprofibrate to rat, mouse and marmoset. Toxicol App. Pharmacol (1988) 95:328–338.
   PubMed Web of Science ®Google Scholar
• MARTINSEN TC, NESJAN N, RONNING K, SANDVIK AK, WALDUM HL: The perwdsome proliferator ciprofibrate induces hypergastrinemia without raising gastric pH. Carcinogenesis (1996) 17:2153–2155.
   PubMed Web of Science ®Google Scholar
• WANG TC, DANGLER CA, CHEN D et al.: Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastroenterology (2000) 118:36–47.
   PubMed Web of Science ®Google Scholar
• ••Article of considerable interest.
   Google Scholar
• LEVI S, BEARDSHALL K, HADDAD G, PLAYFORD R, GHOSH P, SALAM J: Campylobacter pylori and duodenal ulcers: the gastrin link. Lancet (1989) 8648:1167–1168.
   Google Scholar
• •Article of interest.
   Google Scholar
• PARSONNET J, FRIEDMAN G, VANDERSTEEN D et al.: Helicobacter pylori infection and the risk of gastric carcinoma. N Engl. I Med. (1991) 325:1127–1131.
   PubMed Web of Science ®Google Scholar
• HANSEN S, VOLLSET SE, ARDILL JES,et al.: Hypergastrinaemia is a strong predictor of distal gastric adenocarcinoma among Helicobacter pyloriinfected persons. Gastroenterology (1997) 112:A575.
   Google Scholar
• •Article of interest.
   Google Scholar
• HIRSCHOWITZ BI, HABER MM: Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole. Aliment. Pharmacol Titer. (2001) 15:87–103.
   PubMed Web of Science ®Google Scholar
• HIRAYAMA F, TAKAGI S, IWAO E, YOKAYAMA Y, HAGA K, HANADA S: Development of poorly differentiated adenocarcinoma and carcinoid due to long-term Helicobacter pylori colonization in Mongolian gerbils.' Gastroenterol. (1999) 34:450–454.
   Web of Science ®Google Scholar
• WALDUM HL, HAUGEN OA, BRENNA E: Do neuroendocrine cells, and particularly the D-cell, play a role in the development of gastric stump cancer? Cancer Detect. Prey (1994) 18:431–436.
   Google Scholar
• EISSELE R, BRUNNER G, SIMON B, SOLCIA E, ARNOLD R: Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology (1997) 112:707–717.
   PubMedGoogle Scholar
• HAGA Y, NAKATSURE T, SHIBATA Yet al.: Human gastric carcinoid detected during long-term antiulcer therapy of H2 receptor antagonist and proton pump inhibitor. Dig. Dis. Sci. (1998) 43:253–257.
   Google Scholar
• PROCTER GAMBLE COMPANY/ ASTRAZENECA LP: Omeprazole magnesium tablets. NBA (2000) 21:229.
   Google Scholar
• ••Article of considerable interest.
   Google Scholar
• WALDUM HL: Letter to the editor. Aliment. Pharmacol. Ther. (2001) 15:729–730.
   PubMedGoogle Scholar
• GRAHAM JR: Omeprazole and gastric polyposis in humans. Gastroenterology (1993) 104:1584.
   PubMed Web of Science ®Google Scholar
• CHOUDHRY U, WORTH BOYCE H, COPPOLA D: Proton pump inhibitor-associated gastric polyps. A retrospective analysis of their frequency and endoscopic, histologic, and ultrastructural characteristics.Clin. Pathol. (1998)110:615–621.
   Google Scholar
• WALDUM HL, BRENNA E: Personal review: is profound acid inhibition safe? Aliment. Pharmacol. Ther. (2000) 14:15–22.
   Google Scholar
• SANDULEANU S, DEBRUINE A, STRIDSBERG M et al.: Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy. Eur.j Clin. Invest. (2001) 31:802–811.
   PubMed Web of Science ®Google Scholar
• •Article of interest.
   Google Scholar
• KLEVELAND O, SYVERSEN U, SLORDAHL K, WALDUM HL: Hypergastrinemia as a cause of chromogranin A increase in blood in patients suspected to have neuroendocrine tumor. Digestion (2001) 64:71–74.
   PubMed Web of Science ®Google Scholar
• WALDUM HL, SYVERSEN U: Serum chromogranin A in the control of patients on long-term treatment with inhibitors of acid secretion. Ear: Clin. Invest. (2001) 31:741–743.
   PubMed Web of Science ®Google Scholar
• GRIFFIN SM, RAIMES SA: Proton pump inhibitors may mask early gastric cancer. Br. Med. (1998) 317:1606–1607.
   PubMed Web of Science ®Google Scholar
• CORLETO VD, ANNIBALE B, GIBRIL F et al.: Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger-Ellison syndrome? Aliment. Pharmacol. Ther. (2001) 15:1555–1561.
   Web of Science ®Google Scholar
• PALMER SMITH J, WOOD JG, SOLOMON TE: Elevated gastrin levels in patients with colon cancer of adenomatous polyps. Dig. Dis. Sci. (1989) 34:171–174.
   PubMed Web of Science ®Google Scholar
• PALMER SMITH J, SOLOMON TE: Effects of gastrin, proglumide, and somatostatin on growth of human colon cancer. Gastroenterology (1988) 95:1541–1548.
   PubMed Web of Science ®Google Scholar
• HAKANSON R, AXELSON J, PERSSON P, SUNDLER F: Which effects of antral gastrin are physiological? In: Gastrin and Cholecystokinin. Chemistry Physiology and Pharmacology Bali JP, Martinez J (eds) Elsevier, Amsterdam (1987):163–178.
   Google Scholar
• HSING AW, HANSSON L-E, MCLAUGHLIN JK et al.: Pernicious anemia and subsequent cancer. Cancer (1993) 71:745–750.
   PubMed Web of Science ®Google Scholar
• REHFELD JF: Gastrin and colorectalcancer: a never-ending dispute? Gastroenterology (1995) 108:307–1310.
   Google Scholar
• ERICSON LEH, HAKANSON R, LARSON B, OWMAN C, SUNDLER F: Fluorescence and electron microscopy of amine-storing enterochromaffin-like cells in treacheal epithelium of mouse. Z Zellforsch (1972) 124:532–545.
   PubMedGoogle Scholar
• WALDUM HL, RORVIK H, BRENNA E: The gastrointestinal tract and the lungs. Similarities with particular emphasis on the neuroendocrine cells. Sarcoidosis Vasc. Diffuse Lung Dis. (1996) 13:63–65.
   PubMed Web of Science ®Google Scholar
• SETHI T, ROZENGURT E: Gastrin stimulates Ca2+ mobilization and clonal growth in small cell lung cancer cells. Cancer Res. (1992) 52:6031–6035.
   PubMed Web of Science ®Google Scholar
• COOPER CW, SCHWESINGER WH, MAHGOUB AM, ONTJES DA: Thyrocalcitonin: stimulation of secretion by pentagastrin. Science (1971) 172:1238–1240.
   PubMed Web of Science ®Google Scholar
• REUBI JC, WASER B: Unexpected high incidence of cholecystokinin-B/gastrin receptors in human medullary thyroid carcinomas. Int. Cancer(1996) 67:644–647.
   PubMed Web of Science ®Google Scholar
• LEE Y-M, BEINBORN M, MCBRIDE EW, LU M, KOLAKOWSKI LF JR, KOPIN AS: The human brain cholecystokinin-B/gastrin receptor. Cloning and characterization. J. Biol. Chem. (1993) 268:8164–8169.
   PubMed Web of Science ®Google Scholar
• COOK GC: Infective gastroenteritis and its relationship to reduced gastric acidity. Scand. Gastroenterol. (1985) 20(Suppl. 111):17–21.
   Google Scholar
• FRIED M, SIEGRIST H, FREI R et al: Duodenal bacterial overgrowth during treatment in outpatients with omeprazole. Gut (1994) 35:23–26.
   PubMed Web of Science ®Google Scholar
• HORNICK RB, MUSIC SI, WENZEL R et al.: The Broad Street pump revisited: response of volunteers to ingested cholera vibros. Bull. NY Acad. Med. (1971) 47:1181–1191.
   PubMedGoogle Scholar
• ••Article of considerable interest.
   Google Scholar
• SABIN AB: Pathogenesis of poliomyelitis. Reappraisal in the light of new data. Science (1956) 123:1151–1157.
   Google Scholar
• PRUSINER SB: Prions. Proc. Nati Acad. Sci. USA (1998) 95:13363–13383.
   PubMedGoogle Scholar
• SHMAKOV AN, GHOSH S: Prion proteins and the gut: une liaison dangereuse? Gut (2001) 48:443–447.
   PubMed Web of Science ®Google Scholar
• MARTINSEN TC, TAYLOR DM, JOHNSEN R, WALDUM HL: Gastric acidity protects mice against prion infection? Scand.J. Gastroenterol. (2002) 37:497–500.
   PubMed Web of Science ®Google Scholar
• •Article of interest.
   Google Scholar
• WILL RG, IRONSIDE JVV, ZEIDLER M et al.: A new variant of Creutzfeldt-Jakob disease in the UK. Lancet (1996) 347:921–925.
   PubMed Web of Science ®Google Scholar
• SHIBATA D, WEISS LM: Epstein-Barr virus-associated gastric adenocarcinoma. Am.Pathol. (1992) 140:769–774.
   PubMed Web of Science ®Google Scholar
• YUSEN ST, CHUNG LP, LEUNG SY, LUK IS, CHAN SY, HO J: ha situ detection of Epstein-Barr virus in gastric and colorectal adenocarcinomas. Am. .1. Surg. Pathol. (1994) 18:1158–1163.
   PubMed Web of Science ®Google Scholar
• STOCKBRUEGGER RW: Bacterial overgrowth as a consequence of reduced gastric acidity. Scand. Gastroenterol. (1985) 111:7–16.
   Google Scholar
• MOWAT C, CARSWELL A, WIRZ A, MCCOLL KEL: Omeprazole and dietary nitrate independently affect levels of vitamin C and nitrite in gastric juice. Gastroenterology (1999) 116:813–822.
   PubMed Web of Science ®Google Scholar
• KLINKENBERG-KNOL EC, NELIS F, DENT J et al.: Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology (2000) 118:661–669.
   PubMed Web of Science ®Google Scholar
• YEOMANS ND, DENT J: Personal review: alarmism or legitimate concerns about long-term suppression of gastric acid secretion? Aliment. Phannacol Ther: (2000) 14:267–271.
   PubMed Web of Science ®Google Scholar
• LAINE L, AHNEN D, MCCLAIN C, SOLCIA E, WALSH JH: Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment. Pharmacol Ther. (2000) 14:651–668.
   PubMed Web of Science ®Google Scholar